The Strategies and Mechanisms of Immune Checkpoint Inhibitors for Brain Metastases in NSCLC
Brain metastases are more and more common among patients with non-small cell lung cancer (NSCLC). TKI therapy could provide ideal outcomes for patients harboring epidermal growth factor receptor or ALK mutations. For wild-type patients, however, survival is poor because there are few effective treat...
Saved in:
Main Authors: | Ji Li (Author), Min Wang (Author), Shuhui Xu (Author), Yuying Li (Author), Jiatong Li (Author), Jinming Yu (Author), Hui Zhu (Author) |
---|---|
Format: | Book |
Published: |
Frontiers Media S.A.,
2022-05-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
It might be a dead end: immune checkpoint inhibitor therapy in EGFR-mutated NSCLC
by: Ken Akao, et al.
Published: (2024) -
Association of clock-like mutational signature with immune checkpoint inhibitor outcome in patients with melanoma and NSCLC
by: Wei Chong, et al.
Published: (2021) -
A model‐based meta‐analysis of immune‐related adverse events during immune checkpoint inhibitors treatment for NSCLC
by: Renwei Zhang, et al.
Published: (2022) -
Efficacy of immune checkpoint inhibitors in EGFR-Mutant NSCLC patients with EGFR-TKI resistance: A systematic review and meta-analysis
by: Xiaoyu Qian, et al.
Published: (2022) -
Mechanisms of immune checkpoint inhibitor-mediated liver injury
by: Layla Shojaie, et al.
Published: (2021)